The myeloproliferative disorders polycythaemia vera (PV), essential thombocythaemia (ET),
and primary myelofibrosis (PMF) are clonal disorders of multipotent haematopoietic …

The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is
comprised of hematologists, hematopathologists, and laboratory scientists and its main goal …

Background The V617F mutation, which causes the substitution of phenylalanine for valine
at position 617 of the Janus kinase (JAK) 2 gene (JAK2), is often present in patients with …

The Janus kinase 2 mutation, JAK2 617V> F, is myeloid neoplasm-specific; its presence
excludes secondary polycythemia, thrombocytosis, or bone marrow fibrosis from other …

After accounting for misdiagnosis and treatment effect, allele-specific (AS)-PCR detects the
JAK2V617F mutation in> 95% of polycythemia vera (PV) patients. Using database inquiry …

An underlying myeloproliferative disorder (MPD), especially polycythemia vera (PV) or
essential thrombocythemia (ET), is a risk factor for thrombosis. Considering large selected …

In order to investigate the biologic processes underlying and resulting from the
megakaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral …

Abstract JAK2V617F and MPLW515L/K represent recently identified mutations in
myeloproliferative disorders (MPD) that cause dysregulated JAK-STAT signaling, which is …

The clinical and haematological phenotype of patients with myelofibrosis harbouring
MPLW515L/K mutation has not been thoroughly investigated. Of 217 myelofibrosis subjects …

Myeloproliferative disorders (MPDs) constitute a group of hematopoietic malignancies that
feature enhanced proliferation and survival of one or more myeloid lineage cells. William …